Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Chemotherapy as Adjuvant Treatment for Stage III GC/GEJ Adenocarcinoma
NCT06761846Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year disease free survival rate. Started Jan 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT06761846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761846.